PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network said it recently appointed Dr. Nancy L. Lewis as chief scientific officer, effective May 2026, to oversee research programs and clinical initiatives aimed at advancing cancer care.
Lewis joins NCCN from Novartis Pharmaceuticals, where she served as senior clinical program leader, and brings experience in clinical trials for solid tumors and hematologic cancers.
She previously held academic roles as an associate professor at several cancer centers and completed her fellowship at Fox Chase Cancer Center, one of NCCN’s founding institutions.
In the role, Lewis will support the NCCN Oncology Research Program and contribute to the development of NCCN Clinical Practice Guidelines in Oncology and NCCN Guidelines for Patients.
She will also oversee programs including the NCCN Biomarkers Compendium, Radiation Therapy Compendium, and Imaging Appropriate Use Criteria, and will assist with continuing medical education and global and policy initiatives.
“This is a pivotal time for cancer research,” said NCCN CEO Dr. Crystal S. Denlinger, who previously held the chief scientific officer role.
Lewis said she plans to work with NCCN collaborators to address emerging challenges in oncology and improve patient outcomes.
Lewis has received recognition from organizations including the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Cancer Society.
NCCN is a nonprofit alliance of cancer centers focused on research, education, and clinical guidance, including widely used oncology treatment guidelines.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.